Trial intelligence / Profile preview

Randomized Phase III study of short-course radiotherapy plus prolonged preoperative chemotherapy versus standard chemoradiotherapy in high-risk primary rectal cancer

2010-023957-12Phase 3Active

Sponsor
Dutch Colorectal Cancer Group
Start
Feb 2011
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 3, randomised trial of capecitabine and oxaliplatin in rectal cancer (2 arms), sponsored by Dutch Colorectal Cancer Group. Primary endpoint: 3-year disease-free survival. Started Feb 2011; status: active.

02

Drugs

capecitabineoxaliplatin
03

Conditions

rectal cancer

Beyond the preview

Go deeper on 2010-023957-12.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2010-023957-12.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call